Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00100009 · ClinicalTrials.gov registry record · Phase 3
Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration
A Phase 3 study of Macular Degeneration, sponsored by National Eye Institute (NEI).
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT00100009: Completed Phase 3 study of Macular Degeneration, sponsored by National Eye Institute (NEI).
NCT00100009 is a Phase 3 study of Macular Degeneration that has completed, run by National Eye Institute (NEI). The registered enrollment target is 30 participants, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00100009, a Phase 3 study of Macular Degeneration, has completed, sponsored by National Eye Institute (NEI).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular degeneration (AMD). The macula is the part of the retina in the back of the eye that determines central or best vision. AMD can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. This vision loss is caused by the formation of abnormal blood vessels behind the retina that leak blood under the macula. PTD stops the growth of these blood vessels and slows the rate of vision loss; however, it has only a temporary effect and does not work in all patients. Furthermore, it may actually cause some swelling and re-growth of blood vessels. Triamcinolone acetonide can help lessen swelling and scarring. Patients 50 years of age and older with AMD may be eligible for this study. Candidates are screened with a medical history, medical evaluation, and eye examinations (see below). Participants are randomly assigned to one of three treatment groups: 1) PDT plus 1 mg TAC-PF; 2) PDT plus 4 mg TAC-PF; or 3) PDT plus sham injection (a syringe with no needle is pressed against the eye). Treatments are given the day the patient enrolls in the study and then every 3 months for 2 years, as long as the therapy is thought beneficial. Patients who must discontinue TAC-PF injections may still be treated with PDT if medically necessary. In addition to treatment, patients undergo the following tests and procedures: * Eye examination: Visual acuity and eye pressure are measured, and the lens, retina, pupils and eye movements are examined. * Fundus photography: Photographs of the back of the eye are taken using a special camera with a bright flash. * Lens photography: Photographs of the lens are taken to look for development of cataracts. * Fluorescein angiography: Pictures of the retina are taken to look for abnormal blood
Conditions Studied
Interventions
- DRUG Triamcinolone Acetonide
- DRUG TAC-PF
Study Locations (20)
Florida
- Bascom Palmer Eye Institute - Miami
- Central Florida Retina (CFROL) - Orlando
- Retina Associates of Florida - Tampa
Maryland
- Elman Retina Group, P.A. - Baltimore (ERGBM) - Baltimore
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
- Elman Retina Group, P.A. - Pikesville (ERGPM) - Pikesville
Oregon
- Casey Eye Institute-Portland, OR (CEIPO) - Portland
- Retina Northwest (RNWPO) - Portland
Tennessee
- Southeastern Retina Associates (SRAKT) - Knoxville
- Vanderbilt University - Nashville
Arizona
- Retina Associates Southwest (RASTA) - Tucson
California
- Doheny Eye Institute - Los Angeles
Indiana
- Midwest Eye Institute - Indianapolis
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2004-12-09 |
| Est. Completion | 2006-12-20 |
| Phase | Phase 3 |
What the finished NCT00100009 record still lists
NCT00100009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 178-participant average among 26 other Macular Degeneration trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which Triamcinolone Acetonide is the first listed.
NCT00100009 names 20 study sites across 14 states, led by Florida, Maryland, Oregon.
Frequently Asked Questions
What is clinical trial NCT00100009 about?
NCT00100009 is a clinical study titled "Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration". This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular degeneration (AMD). The macula is the part of the retina in the back of the eye t...
What is the current status of trial NCT00100009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2004-12-09. Estimated completion is 2006-12-20.
What conditions does trial NCT00100009 study?
This clinical trial studies the following conditions: Macular Degeneration.
What interventions are being tested in trial NCT00100009?
The interventions under investigation include: Triamcinolone Acetonide (DRUG), TAC-PF (DRUG).
Who is sponsoring clinical trial NCT00100009?
This trial is sponsored by National Eye Institute (NEI), which has 221 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00100009 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00100009's enrollment target sits among peer trials
30 19th of 26 higher than 6 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD
COMPLETED · Phase 3
-
A Study of Genetic and Environmental Factors and Their Effect on Response to Treatment With Lucentis (Ranibizumab) for Wet AMD
COMPLETED · Phase 3
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
COMPLETED · Phase 3
-
Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)
COMPLETED · Phase 3
-
Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)
COMPLETED · Phase 3
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI